Business context and reporting period
The filing is Pieris Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2020. This differs from the company name in the request metadata. Pieris is a clinical-stage biopharmaceutical company developing Anticalin-based medicines, with revenue from licensing and collaboration agreements rather than product sales.
Financial results and liquidity
Amounts below are in U.S. dollars; financial statement amounts have been converted from thousands to millions.
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | $11.2m | $5.3m | $24.5m | $13.9m |
| Operating expenses | $15.9m | $17.6m | $33.0m | $36.8m |
| Operating loss | $(4.7)m | $(12.2)m | $(8.5)m | $(22.9)m |
| Net loss | $(5.0)m | $(11.8)m | $(8.5)m | $(22.1)m |
| Net loss per share | $(0.09) | $(0.24) | $(0.16) | $(0.44) |
| Operating cash flow | Not separately provided | Not separately provided | $(24.9)m | $(25.8)m |
At June 30, cash and cash equivalents were $44.3m and short-term investments were $32.9m, totaling $77.2m. Current assets were $92.0m and current liabilities $18.3m. Total liabilities were $71.1m; the filing reports no debt balance, while operating lease liabilities totaled $15.0m on the balance sheet. Accumulated deficit was $182.7m. The filing does not provide a gross margin figure.
Material changes versus the prior comparable periods
- Q2 revenue more than doubled year over year, principally due to Seattle Genetics revenue recognized after a contract amendment and a $5.0m milestone; lower AstraZeneca activity partly offset the increase. Six-month revenue also benefited from $7.1m of Servier deferred revenue recognized after certain program rights lapsed in March.
- Operating expenses declined year over year, mainly from lower immuno-oncology manufacturing and preclinical costs. Six-month R&D expense fell $3.6m to $24.1m.
- Six-month net loss narrowed to $8.5m from $22.1m, but cash and cash equivalents declined $18.0m from year-end 2019. Cash used in operations was $24.9m.
Outlook, management commentary, risks and unusual items
- Management expected existing cash, cash equivalents and investments to fund operations and capital expenditures for at least 12 months from the August 10, 2020 filing date. It anticipated continued substantial losses and increased cash needs as development advances; it did not expect product-sales revenue in the foreseeable future.
- Management planned to advance PRS-060/AZD1402 toward a Phase 2a study in Q4 2020, subject to collaboration progress. It expected to file an IND for PRS-344 in 2021 and planned to transfer PRS-352 to Servier in 2020.
- In July 2020, the FDA placed PRS-343 Phase 1 studies on partial clinical hold pending an additional in-use and compatibility study. Existing participants could continue treatment, but new enrollment was suspended until the hold was resolved. The company said a planned Phase 2 study remained conditional on completing the requested work.
- On August 10, 2020, after quarter-end, Pieris entered a Phase 2 trial collaboration with Eli Lilly: Pieris would sponsor a PRS-343 combination study and Lilly would supply ramucirumab and provide input. The filing does not state a financial payment under this agreement.
- Servier discontinued co-development of three programs for strategic reasons (PRS-332 in 2019 and two earlier-stage programs in March 2020); it continued work on PRS-344 and PRS-352. Seattle Genetics selected a program for further advancement after a milestone was achieved.
- COVID-19 reduced travel costs; management also identified potential effects on research, development, supply chain and clinical trials. The company disclosed a material weakness in IT general controls and revenue-recognition controls; remediation was ongoing. Management stated no material financial statement misstatements had been identified in connection with these weaknesses.
- No material pending legal proceedings were reported. The company identified clinical-development uncertainty, financing needs, collaboration dependence, regulatory risks and foreign-exchange exposure as risks.
Important facts for investors to verify
- Confirm the filing entity: this 10-Q is for Pieris Pharmaceuticals, Inc., not the company name in the request metadata.
- Track resolution of the PRS-343 partial clinical hold and its effect on enrollment and the planned combination study.
- Assess cash runway against the reported $24.9m six-month operating cash outflow, capital spending and management’s at-least-12-month estimate.
- Separate recurring collaboration activity from milestone and deferred-revenue recognition when assessing revenue sustainability.
- Monitor remediation of the disclosed material weaknesses and any subsequent changes in control effectiveness.